Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2000

01-06-2000 | Review Article

Assessing Medication Appropriateness in the Elderly

A Review of Available Measures

Authors: Dr Penny S. Shelton, Michelle A. Fritsch, Mollie A. Scott

Published in: Drugs & Aging | Issue 6/2000

Login to get access

Abstract

The disproportionate use of medications, combined with age-related pharmacokinetic and pharmacodynamic changes, places older adults at high risk for medication related problems (MRPs). MRPs demonstrate significant morbidity, mortality and economic impact among healthcare systems. The negative outcomes associated with MRPs emphasise the need for more careful and thorough assessments of drug therapy among older adults.
In the 1990s a number of methods and instruments were developed to assist in the assessment of medication appropriateness. These tools may be categorised by criteria as: implicit, explicit or one utilising a combination of implicit and explicit criteria. This article reviews these available tools and outlines the advantages and disadvantages of each. In conclusion, those instruments considered to be comprised of both implicit and explicit criteria offer a more thorough assessment of medication appropriateness.
Literature
1.
Hall WJ. Update in geriatrics. Ann Intern Med 1997; 127(7): 557–64PubMed
2.
Stewart RB. Drag use in the elderly. In: Delafuente JC, Stewart RB, editors. Therapeutics in the elderly. 2nd ed. Cincinnati: Harvey Whitney Books, 1995: 174–89
3.
Broderick E. Prescribing patterns for nursing home residents in the US: the reality and the vision. Drags Aging 1997; 11: 255–60CrossRef
4.
Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: data from the Established Populations for Epidemiologic Studies of the Elderly. J Gerontol 1992; 47: M137–44PubMedCrossRef
5.
Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drag reactions and related resource use: a study of community-dwelling persons 65 years of age and older. Ann Intern Med 1992; 117: 634–40PubMed
6.
Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945–8PubMed
7.
May JR. Adverse drug reactions and interactions. In: Dipiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: apathophysiologic approach. 3rd ed. Stamford: Appleton and Lange, 1997: 101–16
8.
Rochon PA, Gurwitz JH. Optimising drag treatment for elderly people: the prescibing cascade. BMJ 1997; 315: 1096–9PubMedCrossRef
9.
Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 1997; 157: 2205–10PubMedCrossRef
10.
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997; 277(4): 301–6PubMedCrossRef
11.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5PubMedCrossRef
12.
Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–56PubMedCrossRef
13.
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drag events: implications for prevention. JAMA 1995; 274: 29–34PubMedCrossRef
14.
Beers MH, Storrie M, Lee G. Potential adverse drag interactions in the emergency room: an issue in the quality of care. Ann Intern Med 1990; 112: 61–4PubMed
15.
Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Practice 1991; 8: 234–6CrossRef
16.
Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; II: 564–7CrossRef
17.
Jankel CA, McMillan JA, Martin BC. Effect of drag interactions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm 1994; 51: 661–6PubMed
18.
Hamilton RA, Gordon T. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992; 26: 1507–11PubMed
19.
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157: 1531–6PubMedCrossRef
20.
Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592–6PubMedCrossRef
21.
Perez-Stable EJ, Miranda J, Munoz RF, et al. Depression in medical outpatients: underrecognition and misdiagnosis. Arch Intern Med 1990; 150: 1083–8PubMedCrossRef
22.
Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin the long-term care setting. Arch Intern Med 1997; 157: 978–84PubMedCrossRef
23.
Stuck AE, Tamai IY. Medication management in the home. Clin Geriatr Med 1991; 7(4): 733–48PubMed
24.
Monane M, Monane S, Semla T. Optimal medication use in elders: key to successful aging. West J Med 1997; 167: 233–7PubMed
25.
Montamat SC, Cusack BJ, Vestal RE. Management of drag therapy in the elderly. N Engl J Med 1989; 321: 303–9PubMedCrossRef
26.
Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992; 117: 684–9PubMed
27.
Spore DL, Mor V, Larrat P, et al. Inappropriate drag prescriptions for elderly residents of board and care facilities. Am J Pub Health 1997; 87: 404–9CrossRef
28.
Aparasu RR, Fliginger SE. Inappropriate medication prescribing for the elderly by office-based physicians. Ann Pharmacother 1997; 31: 823–9PubMed
29.
Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. Can Med Assoc J 1994; 150(11): 1801–9
30.
Torrible SJ, Hogan DB. Medication use and rural seniors: who really knows what they are taking? Can Fam Physician 1997; 43: 893–989PubMed
31.
Der EH, Rubenstein LZ, Choy GS. The benefits of in-home pharmacy evaluation for older persons. J Am Geriatr Soc 1997; 45(2): 211–4
32.
Hunter KA, Florio ER, Langberg RG. Pharmaceutical care for home-dwelling elderly persons: a determination of need and program description. Gerontologist 1996; 36(4): 543–8PubMedCrossRef
33.
Schrader SL, Dressing B, Blue R, et al. The Medication Reduction Project: combatting polypharmacy in South Dakota elders through community-based interventions. S D J Med 1996; 49(12): 441–8PubMed
34.
Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825–32PubMedCrossRef
35.
Shelton PS, Hanlon JT, Landsman PB, et al. Reliability of drug utilization evaluation as an assessment of medication appropriateness. Ann Pharmacother 1997; 31: 533–42PubMed
36.
Morris JN, Hawes C, Murphy K, et al. Resident assessment instrument training manual and resource guide. Natick (MA): Eliot Press, 1991
37.
Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45: 1045–51PubMedCrossRef
38.
Hamdy RC, Moore SW, Whalen K, et al. Reducing polypharmacy in extended care. South Med J 1995; 88(5): 534–8PubMedCrossRef
39.
Owens NJ, Sherburne NJ, Silliman RA, et al. The Senior Care Study: the optimal use of medications in acutely ill older patients. J Am Geriatr Soc 1990; 38: 1082–7PubMed
40.
Johnson RE, Campbell WH, Azevedo DJ, et al. Studying the impact of patient drag profiles in an HMO. Med Care 1976; 14: 799–807PubMedCrossRef
41.
Koepsell TD, Gurtel AL, Diehr PH, et al. The Seattle evaluation of computerized drag profiles: effects on prescribing practice and resource use. Am J Pub Health 1983; 73: 850–5CrossRef
42.
Tamai IY, Rubenstein LZ, Josephson KR, et al. Impact of computerized drag profiles and a consulting pharmacist on outpatient prescribing patterns: a clinical trial. Drag Intell Clin Pharm 1987; 21: 890–5
43.
Stuck AE, Beers MH, Steiner A, et al. Inappropriate medication use in community-residing older persons. Arch Intern Med 1994; 154: 2195–200PubMedCrossRef
44.
Anderson GM, Beers MH, Kerluke K. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. J Evalu Clin Pract 1997; 3(4): 283–94CrossRef
45.
Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272(4): 292–6PubMedCrossRef
46.
McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. Can Med Assoc J 1997; 156(3): 385–91
47.
Oborne CA, Batty GM, Maskrey V, et al. Development of prescribing indicators for elderly medical inpatients. Br J Clin Pharmacol 1997; 43: 91–7PubMedCrossRef
48.
Knapp DA. Development of criteria for drug utilization review. Clin Pharm Ther 1991; 50(5): 600–5
49.
Davidson HE, Chamberlain TM, Hernandez P, et al. Drug-use evaluation, part II: Drug-use analysis in pharmaceutical care and quality assurance. Consult Pharmacist 1991; 6(10): 836–43
50.
Ben-Joseph R, Segal R, Russell WL, et al. Evaluating the value, accuracy and operational feasibility of DUE criteria. Formulary 1995; 30: 280–3PubMed
51.
Winslade NE, Bajcare JM, Bombassaro AM, et al. Pharmacist’s management of drug-related problems: a tool for teaching and providing pharmaceutical care. Pharmacotherapy 1997; 17(4): 801–9PubMed
52.
Robertson KE. Process for preventing or identifying and resolving problems in drug therapy. Am J Health Syst Pharm 1996; 53: 639–50PubMed
53.
Newton PF, Levinson W, Maslen D. The Geriatric Medication Algorithm: a pilot study. J Gen Intern Med 1994; 9(3): 164–7PubMedCrossRef
54.
Lipton HL, Bird JA, Bero LA, et al. Assessing the appropriateness of physician prescribing for geriatric outpatients: development and testing of an instrument. J Pharm Technol 1993; 9: 107–13PubMed
55.
Owens NJ, Fretwell MD, Willey C, et al. Distinquishing between the fit and frail elderly, and optimising pharmacotherapy. Drugs Aging 1994; 4(1): 47–55PubMedCrossRef
56.
Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist 1990; 30: 293–307PubMedCrossRef
57.
Riley K. Putting the MDS 2.0 to work in long-term care. Consult Pharmacist 1996; 11(7): 669–75
58.
Riley K. RAPs and the consultant pharmacist. Consult Pharmacist 1997; 12(1): 32–4
59.
Morris JN, Fries BE, Knight S, et al. Comprehensive clinical assessment in community setting: applicability of the MDSHC. J Am Geriatr Soc 1997; 45: 1017–24PubMed
60.
Morris JN, Nonemaker S, Murphy K, et al. A commitment to change: revision of HCFA’s RAI. J Am Geriatr Soc 1997; 45: 1011–16PubMed
61.
Ouslander JG. The resident assessment instrument (RAI): promises and pitfalls. J Am Geriatr Soc 1997; 45: 975–6PubMed
62.
Losben NL. Putting the MDS 2.0 to work to identify and monitor at-risk elderly. Consult Pharmacist 1997; 12(5): 520–34
63.
Tobias DE, Feinberg JL, Troutman WG. The MDS-Med Guide: a tool for the new millenium. Consult Pharmacist 1999; 14(8): 831–60
64.
Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47: 891–6PubMedCrossRef
65.
Schmader KE, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994; 42: 1241–7PubMed
66.
Schmader KE, Hanlon JT, Landsman PB, et al. Inappropriate prescribing and health outcomes in elderly veteran outpatients. Ann Pharmacother 1997; 31: 529–33PubMed
67.
Fitzgerald LS, Hanlon JT, Shelton PS, et al. Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother 1997; 31: 543–8PubMed
68.
Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef
69.
Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. J Am Med Assoc 1979; 242: 623–32CrossRef
70.
Hepler DC, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43PubMed
Metadata
Title
Assessing Medication Appropriateness in the Elderly
A Review of Available Measures
Authors
Dr Penny S. Shelton
Michelle A. Fritsch
Mollie A. Scott
Publication date
01-06-2000
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2000
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200016060-00004

Other articles of this Issue 6/2000

Drugs & Aging 6/2000 Go to the issue

Adis Drug Evaluation

Risperidone

Disease Management

Onychomycosis in the Elderly

Review Article

Use of Oral Anticoagulants in Older Patients

Leading Article

Potential Role of Cannabinoids in Parkinson’s Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits